Skip to content
back
back
back
back
back
You are about to leave Fidia Pharma Middle East F.Z.E. website.
All information you are about to see is related to a specific selected market, including the products’ portfolio, and therefore comply to different local regulations.
PROCEED
cta

Our financial data in facts & figures

OUR REVENUES

EBITDA (2021)
75,5 (20,4% of turnover)
EBIT (2021)
53,8 (14,5% of turnover)
NET RESULT (2021)
36,4 (9,8% of turnover)

Related Documents

Consolidated Financial Statements Fidia Farmaceutici Group as at 31 December 2021
OUR FIGURES BY FOCUS AREA (€ Millions, 2021)
145,704972397088 € Millions
JOINT CARE
43,5174575427342 € Millions
SKIN CARE
72,0400280058411 € Millions
EYE CARE
4,47464872 € Millions
ACTIVE SUBSTANCES
28,5614007940102 € Millions
CORTICOSTEROIDS
76,883507540341 € Millions
OTHER
OUR FIGURES BY PRODUCT CATEGORY (€ Millions, 2021)
33
PRESCRIPTION DRUGS
43
MEDICAL DEVICES
5
VACCINES
19
OTHER
OUR FIGURES BY GEOGRAPHICAL AREA (€ Millions, 2021)
190,077123810019 € Millions
ITALY
88,7572507949103 € Millions
EUROPE
13,31175631 € Millions
MENA
53,5833368677323 € Millions
USA
25,4699832173382 € Millions
RoW

OUR GROUP

GOVERNANCE
Find out more
You are about to leave Fidia Pharma Middle East F.Z.E. website.
All information you are about to see is related to a specific selected market, including the products’ portfolio, and therefore comply to different local regulations.
PROCEED
cta